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BfR reviews monograph of the International Agency for Cancer Research 
(IARC) on glyphosate - divergence procedure within the WHO still in progress 
 
BfR Communication No. 024/2015 of 30 July 2015 
 
Following a review of all available studies, glyphosate, an active substance used in pesti-
cides, has been assessed as non-carcinogenic for humans by the competent national, Euro-
pean and other international institutions for health assessment including the WHO/FAO Joint 
Meeting on Pesticide Residues (JMPR) based on the current data and the assumption of 
intended uses. The International Agency for Cancer Research (IARC) of the World Health 
Organization (WHO) recently classifies glyphosate as a carcinogenic substance in Group 2A, 
in IARC words “Probably carcinogenic to humans”, based on the available and evaluated 
studies by IARC. This classification was initially published in a short report in the "Lancet 
Oncology" journal on 20 March 2015 but was not explained scientifically in detail. The full 
report on glyphosate from the IARC monograph (Volume 12) has been publicly available 
since 29 July 2015, and the Federal Institute for Risk Assessment (BfR) is reviewing the 
monograph with regard to documentation that was previously not taken into account, the 
assessment findings, quality aspects and methodology. Germany – as the rapporteur mem-
ber state for the active substance glyphosate within the framework of active substance ap-
proval - is also forwarding the findings to EFSA and ECHA. The WHO itself has set up an “ad 
hoc expert task force" to compare the publications considered by its own bodies IARC and 
the JMPR to identify new studies to clarify the reasons for the different assessments. This 
process is known as a scientific divergence procedure within the WHO. In addition, the Ger-
man government has commissioned the BfR to conduct a scientific review of the IARC mon-
ograph. 
 
With regard to a potential carcinogenicity of glyphosate, IARC concludes that there is only 
limited evidence for Cancer in humans. IARC states that the available epidemiological stud-
ies provide only limited evidence of a statistical connection between exposure to glyphosate 
and an increased risk of non-Hodgkin lymphoma, a neoplastic disease of the lymphatic sys-
tem. In its classification, IARC points to findings of carcinogenicity studies as sufficient evi-
dence for cancer in experimental animals. These findings are also evaluated by the BfR and 
have already been assessed in the revised assessment report (RAR) in the context of the EU 
active substance evaluation procedure. This report was submitted in December 2013 to EF-
SA and was as part of the public consultation process in April 2014, which means that IARC 
also had access to these studies and the draft conclusions.  
 
Many of the studies on possible carcinogenicity and genotoxicity that are currently the sub-
ject of discussion in the scientific world do not use the pure active substance glyphosate but 
only as part of a formulation, in other words in the form of a commercially available product 
together with various other components, such as co-formulants and together with other ac-
tive substances. Especially, as the toxicity of the co-formulants may be higher than that of 
the active substance glyphosate, and as the exact composition is frequently not described in 
published articles in scientific journals, the informative value of the studies that used agents 
containing glyphosate is sometimes low with regard to the active substance evaluation within 
the framework of the EU approval procedure.  
 
The fact that different bodies assess issues or methods differently due to differing information 
and assessments of experimental data is part and parcel of the scientific risk assessment 
process. 
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The BfR has enclosed a preliminary assessment of the short publication of IARC concerning 
the potential carcinogenic effect of glyphosate in its revised report and has recommended 
that a renewed approval process for glyphosate should take account of a detailed assess-
ment of the IARC monograph. 
(http://www.bfr.bund.de/cm/349/bfr-contribution-to-the-eu-approval-process-of-glyphosate-is-
finalised.pdf) 
 
EFSA is to assess the findings of a report by the IARC which concludes that the herbicide 
glyphosate is probably carcinogenic to humans.  
http://www.efsa.europa.eu/en/press/news/150730.htm 
The BfR is currently also requested by EFSA to review the classification published by IARC 
and will first complete its review of this scientific assessment by IARC before issuing its 
comments.  
 
The WHO Taskforce should compare the publications considered by IARC and those con-
sidered by the JMPR, identify those that have not been considered by either IARC or JMPR 
and should consider whether newly available genotoxicity studies provide evidence that any 
of the compounds could be genotoxic. The Taskforce should report back to JMPR in Sep-
tember 2015 for further discussion and action. 
 
More information: 
 
Glyphosate FAQ 
http://www.bfr.bund.de/en/frequently_asked_questions_on_the_health_assessment_of_glyp
hosate-127871.html  
 
Glyphosate in the A-Z index of the BfR 
http://www.bfr.bund.de/en/a-z_index/glyphosate-193962.html  
 
BfR-contribution to the EU-approval process of glyphosate is finalised 
http://www.bfr.bund.de/cm/349/bfr-contribution-to-the-eu-approval-process-of-glyphosate-is-
finalised.pdf  
